This requires Flash to play. Click here to download.
MERCK

The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Zolinza® [vorinostat] capsules Reactivate Expression
Home About ZOLINZA Efficacy Safety Profile Dosage Reimbursement Physician Resources Patient Education CTCL Overview Prescribing Information Patient Product Information
Patient Product Information

Visible Improvements in CTCL
With ZOLINZA*

This requires Flash to play. Click here to download.

Visible Improvements in CTCL With ZOLINZA
  • Cutaneous T-cell lymphomas are a heterogeneous group of cutaneous non-Hodgkin’s lymphomas,1 the 2 most common forms of which are mycosis fungoides (MF) and Sézary syndrome (SS).
Reference: 1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785.

Study Design

Open-label, single-agent, multicenter trial in patients (N=74) treated with ZOLINZA 400 mg once daily. Patients studied were aged 39 to 83 years (median 60 years); 48.6% female and 51.4% male; 82.4% white, 14.9% black, 1.4% Asian, and 1.4% other.

Objective response (primary end point)=either complete clinical response (CCR), defined as no evidence of disease, or partial response (PR), defined as a ≥50% decrease in SWAT skin assessment score compared with baseline. Both CCR and PR had to be maintained for at least 4 weeks.

Selected Important Safety Information

  • QTc prolongation has been observed. Monitor electrolytes and ECGs at baseline and periodically during treatment. Administer with caution in patients who have or may develop QTc prolongation. Hypokalemia or hypomagnesemia should be corrected before administering ZOLINZA.

Before prescribing ZOLINZA, please read the physician Prescribing Information. The Patient Product Information is also available.

Back to Top


Home | Patient Product Information | Prescribing Information
ZOLINZA is a registered trademark of Merck & Co., Inc. Copyright © 2008 Merck & Co., Inc. All rights reserved.

This site is intended only for healthcare professionals of the United States, its territories, and Puerto Rico.

20850991(1)-04/08-ZOL
For general information and other services for physicians
MERCK MEDICUSMERCK SOURCEMERCKServices
MerckMedicus, MerckSource, and MerckServices are trademarks of Merck & Co., Inc.